Ireland Overhauls Biopharma Tariffs to Spur RD and Trade
Ireland has released a biopharmaceutical tariff adjustment plan aimed at reducing R&D and compliance costs, and strengthening its global competitiveness. The new policy focuses on tax reductions for R&D equipment, adaptation to new EU regulations, incentives for high-value drug exports, and restrictions on low-value-added product exports. This move aims to address challenges such as the impact of new EU regulations and increased global competition. It is expected to promote the quality and efficiency of Ireland's biopharmaceutical industry, optimize the global trade landscape, and inject new impetus into Sino-Irish and EU-Irish pharmaceutical trade.
